DETERMINATION OF PHARMACOKINETIC PARAMETERS FROM DISTRIBUTION STUDY FOLLOWING DEVELOPMENT AND VALIDATION OF A SENSITIVE LC-MS METHOD IN TISSUE MATRICES FOR 2-(4-ETHOXYPHENYLSULPHONAMIDO) PENTANEDIAMIDE, AN INVESTIGATIONAL ANTICANCER AGENT

NILUFA YEASMIN; SUVASISH MISHRA; SUBRATA SEN

doi:10.22159/ijap.2024v16i4.51246

Authors

NILUFA YEASMIN A.P.C. Ray Memorial Cancer Chemotherapeutic Research Unit, College of Pharmaceutical Sciences, Berhampur, Odisha affiliated to Biju Patnaik University of Technology, Rourkela, Odisha-769015, India https://orcid.org/0009-0005-3425-0205
SUVASISH MISHRA A.P.C. Ray Memorial Cancer Chemotherapeutic Research Unit, College of Pharmaceutical Sciences, Berhampur, Odisha affiliated to Biju Patnaik University of Technology, Rourkela, Odisha-769015, India https://orcid.org/0000-0001-5738-6299
SUBRATA SEN A.P.C. Ray Memorial Cancer Chemotherapeutic Research Unit, College of Pharmaceutical Sciences, Berhampur, Odisha affiliated to Biju Patnaik University of Technology, Rourkela, Odisha-769015, India

DOI:

https://doi.org/10.22159/ijap.2024v16i4.51246

Keywords:

lC-MS, Validation, Tissue distribution, PK solver software

Abstract

Objective: The aim of this study was to develop and validate bioanalytical methods for estimation of 2-(4-ethoxyphenyl sulphamido) pentanediamide (PC), an investigational anticancer agent, in various organ/tissue matrices to study various Pharmacokinetic parameters using lC-MS.

Methods: Freshly prepared tissue homogenates from Sprague-Dawley rats were used as matrices to develop the bioanalytical method in lC-MS to determine Cmax, Tmax, AUC_0-t, AUC_0-inf, T_1/2, and mean Residence Time (MRT). The distribution study was conducted by administering PC orally to Sprague-Dawley rats and quantifying PC in different excised organs at different points. A non-compartmental analysis was done using ‘PK solver’ software.

Results: In all the tissue matrices, the concentrations of PC were found in the linear range of 10 to 5000 ng/ml. High level of precision, accuracy, and recovery, with negligible matrix effects, were found. PC was distributed in all tissues except the brain. Pharmacokinetic parameters such as Tmax and MRT were between 1.11±0.12 to 2.33±0.11 h and 2.17±0.16 to 4.01±0.25 h respectively in the liver, lung, heart, spleen, kidney, and thymus.

Conclusion: Simple and sensitive lC-MS methods for PC in different tissue matrices were developed and validated. As PC does not cross Blood Brain Barrier (BBB), it will not adversely affect Central Nervous System (CNS). PC is absorbed fast from Gastro Intestinal Tract (GIT) to blood and subsequently reaches the different tissues. Consequently, a fast onset of action will be seen. To sum up, PC is a probable potential anticancer agent with no or minimal adverse effects on CNS.

Downloads

Download data is not yet available.

References

Saha A, Sarker K, Ghosh A, Mishra S, Sen S. Rational design, synthesis, and in vitro evaluation of n-(4-Ethoxyphenylsulfonyl)-l-glutamic acid analogues as antiangiogenic and anticancer agents on multiple myeloma. Indian Drugs. 2021;57(12):26-35. doi: 10.53879/id.57.12.12807.

Yeasmin N, Mishra S, Sarker K, Sen S. Bioanalytical method development and validation of 2-(4-ethoxyphenyl sulphonamido) pentane-diamide, a novel antitumor and antiangiogenic agent, in rat serum and application of the method in determination of pharmacokinetic parameters. Int J App Pharm. 2024 Jan;16(1):194-201. doi: 10.22159/ijap.2024v16i1.49426.

Nandi U, Dan S, Pal TK. Development and validation of a liquid chromatography–mass spectrometry method for simultaneous determination of metoprolol and telmisartan in rat plasma and its application to pharmacokinetic study. J Pharm Investig. 2015;45(3):329-40. doi: 10.1007/s40005-015-0180-5.

De S, Dey S, Shah S. Simultaneous determination of atorvastatin and atenolol in rabbit plasma by RP-HPLC method and its application in pharmacokinetic study. Int J Curr Pharm Res. 2022;14(2):72-8. doi: 10.22159/ijcpr.2022v14i2.1986.

Sunder BS, Mittal AK. Bio-analytical method development and validation for simultaneous determination of ledipasvir and sofosbuvir drugs in human plasma by RP-HPLC method. Int J Curr Pharm Sci 2018;10(3):21-6. doi: 10.22159/ijcpr.2018v10i3.27223.

Tan A, Awaiye K. Use of internal standards in lC-MS bioanalysis, Handbook of lC-MS bioanalysis: best practices, experimental protocols, and regulations. 1st ed. John Wiley & Sons, Inc.; 2013.

Bioanalytical method validation-guidance for industry, U. S. Department of health and human services, food and drug administration, center for drug evaluation and research (CDER), center for veterinary medicine (CVM); 2018.

Crutchfield CA, Marzinke MA. Bioanalytical development and validation of liquid chromatographic-tandem mass spectrometric methods for the quantification of total and free cefazolin in human plasma and cord blood. Pract Lab Med. 2015 Mar 14;1:12-21. doi: 10.1016/j.plabm.2015.03.003, PMID 28932794.

Moein MM, Beqqali El A, Abdel Rehim M. Bioanalytical method development and validation: critical concepts and strategies. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Feb 1;1043:3-11. doi: 10.1016/j.jchromb.2016.09.028, PMID 27720355.

Fisher EN, Melnikov ES, Gegeckori V, Potoldykova NV, Enikeev DV, Pavlenko KA. Development and validation of an lC-MS/MS method for simultaneous determination of short peptide-based drugs in human blood plasma. Molecules. 2022 Nov 14;27(22):7831. doi: 10.3390/molecules27227831, PMID 36431933.

Li R, Fan H, Gu Y, Si D, Liang W. Determination of Boc5 in rat plasma by HPLC–MS/MS and its application to a pharmacokinetic study. Chromatographia. 2012;75(13-14):721-7. doi: 10.1007/s10337-012-2248-y.

Leng G, Zuo Y, Hu J, Yu F, Liu W. Liquid chromatography tandem mass spectrometry method for determination of fulvestrant in rat plasma and its application to pharmacokinetic studies of a novel fulvestrant microcrystal. Biomed Chromatogr. 2020 Oct;34(10):e4912. doi: 10.1002/bmc.4912, PMID 32496589.

Zhang Yang Xm, Xl, Chen Yc. lC Method for determination of ginkgolic acids in mice plasma and its application to a pharmacokinetic study. Chroma. 2009;69:593-6. doi: 10.1365/s10337-008-0903-0.

Das D, Halder D, Bose A, Shaw TK, Saha C, Kumar De P. Determination of metformin and sitagliptin in healthy human volunteers’ blood plasma and its bioequivalence study under fasting condition. Int J App Pharm. 2022;14(6):42-50. doi: 10.22159/ijap.2022v14i6.45140.

Gurav P, Damle M. Bioanalytical method for estimation of teriflunomide in human plasma. Int J Pharm Pharm Sci. 2022;14(9):19-23. doi: 10.22159/ijpps.2022v14i9.45151.

Alumuri T, Merugu K, Amarababu NL, Kurnool A. Peramivir and related impurities in rat plasma and its applications in pharmacokinetic studies (Bioanalytical method development and validation by lC-MS/MS). Int J App Pharm. 2022;14(5):53-61. doi: 10.22159/ijap.2022v14i5.45457.

Inturi R, Raju MD, Basaveswara Rao MV, Inturi S. Pharmacokinetic investigation of remogliflozin in rat plasma samples by high-throughput HPLC-MS-MS. Int J App Pharm. 2022;14(6):178-85. doi: 10.22159/ijap.2022v14i6.45700.

Putriana NA, Rusdiana T, Rostinawati T, Akbar MR, Nurfuadah I. Validation of warfarin analysis method in human blood plasma using high-performance liquid chromatography with fluorescence detection. Int J App Pharm. 2022;14(5):132-8. doi: 10.22159/ijap.2022.v14s5.27.

Agbokponto JE, Yemoa LA, Assanhou AG, Liu R, Ganfon H, Ding L. Liquid chromatography tandem mass spectrometry determination method of bencycloquidium bromide: application to drug interaction study in human. Int J Pharm Pharm Sci. 2021;13(10):43-6. doi: 10.22159/ijpps.2021v13i10.5791.

Elham G, Sima S, Javad S, Shahram S. Analytical method validation, pharmacokinetics and bioequivalence study of dimethyl fumarate in healthy Iranian volunteers. Int J Pharm Pharm Sci. 2021;13(9):6-10. doi: 10.22159/ijpps.2021v13i9.42328.

Nimmakayala MR, Kolli D, Durga Bhavani PN. Bioanalytical method development and validation of maralixibat in rat plasma by lC-MS/MS detection and its application to a pharmacokinetic study. Int J App Pharm. 2023;15(4):166-72. doi: 10.22159/ijap.2023v15i4.47768.

da Costa JC, Motta EV, Barreto F, de Araujo BV, Derendorf H, Bastos JK. Development and validation of a sensitive UFLC−MS/MS method for quantification of quercitrin in plasma: application to a tissue distribution study. ACS Omega. 2019;4(2):3527-33. doi: 10.1021/acsomega.8b03154.

Wang L, Li X, Mi L, Shen X, Feng T, Liu X. Study on pharmacokinetics, tissue distribution, and excretion of phloretin and its prodrug 2′,4′,6′,4-Tetra-O-acetylphloretin in rats using LC–MS/MS. Acta Chromatogr. 2017;31(1):63-70. doi: 10.1556/1326.2017.00363.

Xu S, Yu J, Zhan J, Yang L, Guo L, Xu Y. Pharmacokinetics, tissue distribution, and metabolism study of icariin in rat. BioMed Res Int. 2017;4684962. doi: 10.1155/2017/4684962, PMID 29259982.

Chen Y, Yan Q, Zhong M, Zhao Q, liu J, Di D. Study on pharmacokinetics and tissue distribution of the isocorydine derivative (AICD) in rats by HPLC-DAD method. Acta Pharm Sin B. 2015;5(3):238-45. doi: 10.1016/j.apsb.2015.03.012, PMID 26579452.

G KK, Thaggikuppe Krishnamurthy P, Ammu VV RK, Vishwanath K, Narenderan ST, Babu B. Development and validation of a sensitive lC-MS/MS method for pioglitazone: application towards pharmacokinetic and tissue distribution study in rats. RSC Adv. 2021;11(19):11437-43. doi: 10.1039/d1ra01126j, PMID 35423625.

Ekpenyong O, Gao X, Ma J, Cooper C, Nguyen L, Olaleye OA. Pre-clinical pharmacokinetics, tissue distribution and physicochemical studies of CLBQ14, a novel methionine aminopeptidase inhibitor for the treatment of infectious diseases. Drug Des Dev Ther. 2020;14:1263-77. doi: 10.2147/DDDT.S238148.

Hu X, Ding L, Cao S, Cheng L, Wang K, Guang C. Pharmacokinetics, tissue distribution and excretion of paeonol and its major metabolites in rats provide a further insight into paeonol effectiveness. Front Pharmacol. 2020;11:190. doi: 10.3389/fphar.2020.00190, PMID 32180731.

Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput Methods Programs Biomed. 2010 Sep;99(3):306-14. doi: 10.1016/j.cmpb.2010.01.007, PMID 20176408.

Dai MS, Chao TC, Chiu CF, Lu YS, Shiah HS, Jackson CGCA, Hung N, Zhi J, Cutler DL, Kwan R, Kramer D, Chan WK, Qin A, Tseng KC, Hung CT, Chao TY. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. Ther Adv Med Oncol. 2023 Jul 21;15:17588359231183680. doi: 10.1177/17588359231183680.

https://go.drugbank.com/drugs/DB01268 [Last acceseed on 18 Jun 2024].